Download full-text PDF

Source

Publication Analysis

Top Keywords

[immunologic reactivity
4
reactivity patients
4
patients early
4
early gastric
4
gastric cancer]
4
[immunologic
1
patients
1
early
1
gastric
1
cancer]
1

Similar Publications

Objective: Evaluate the effect of white noise intervention on sleep quality and immunological indicators of patients with breast cancer undergoing neoadjuvant chemotherapy (NAC).

Methods: From January 2020 to December 2022, 104 newly diagnosed female patients (the number of people who met the inclusion criteria) with breast cancer who were confirmed to be preoperative NAC by puncture pathology were selected for a randomised single-blind trial. The patients were randomly divided into an observation group and a control group, with 52 cases in each group.

View Article and Find Full Text PDF

Background: Accumulation of β-amyloid (Aβ) and tau proteins can predict the risk of Alzheimer's disease (AD) at asymptomatic stages and are promising measures for screening individuals at risk. However, not all individuals with Aβ and tau pathology progress to AD; some remain cognitively healthy. That variability challenges prediction accuracy and incorporation of AD pathology into clinical practice.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

FUJIREBIO IINC., Hachioji, Tokyo, Japan.

Background: There is increasing evidence that the pathogenesis of Alzheimer's disease (AD) involves various immunological responses. Indeed, astrocyte reactivity or astrocytosis is a pathological process that is commonly found surrounding amyloid-β plaques in the brains of AD patients. Although the exact role of astrocytosis is still unrevealed, monitoring astrocyte activity using biomarkers leads to a better understanding of the underlying mechanism of AD pathogenesis.

View Article and Find Full Text PDF

Recombinant antibodies and, more recently, T cell receptor (TCR)-engineered T cell therapies represent two immunological strategies that have come to the forefront of clinical interest for targeting intracellular neoantigens in benign and malignant diseases. T cell-based therapies targeting neoantigens use T cells expressing a recombinant complete TCR (TCR-T cell), a chimeric antigen receptor (CAR) with the variable domains of a neoepitope-reactive TCR as a binding domain (TCR-CAR-T cell) or a TCR-like antibody as a binding domain (TCR-like CAR-T cell). Furthermore, the synthetic T cell receptor and antigen receptor (STAR) and heterodimeric TCR-like CAR (T-CAR) are designed as a double-chain TCRαβ-based receptor with variable regions of immunoglobulin heavy and light chains (VH and VL) fused to TCR-Cα and TCR-Cβ, respectively, resulting in TCR signaling.

View Article and Find Full Text PDF

There is a high medical need to develop new strategies for the treatment of patients with acute myeloid leukemia (AML) refractory to conventional therapy. In vitro, the combinations of the blast-modulatory response modifiers GM-CSF + Prostaglandin E1, (summarized as Kit M) have been shown to convert myeloid leukemic blasts into antigen-presenting dendritic cells of leukemic origin (DC) that were able to (re-)activate the innate and adaptive immune system, direct it specifically against leukemic blasts, and induce memory cells. This study aimed to investigate the immune modulatory capacity and antileukemic efficacy of Kit M in vivo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!